35
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Prolonged Paralysis After Neuromuscular Blockade

Pages 419-426 | Published online: 25 Sep 2008
 

Abstract

Non-depolarizing neuromuscular blocking agents have been used with increasing fLequency in critically ill patients. Recently, numerous reports have described patients with prolonged muscle weakiiess ajer use of these agents for more than two days. Brief weakness lasting several hours to several days is likely the result of prolonged neuromuscular blockade, while more prolonged weakness lasting several weeks to months is likely caused by a myopathy. Specijic features of this myopathic disorder are reviewed. Clinically, patients have flaccid paralysis with intact sensation and cognition. Electrodiagnostic findings include decreased M-wave amplitudes, mild positive waves and jibrillations and small, polyphasic motor unit potentials. Muscle biopsyfindings include atrophy of type I and type II fibers, myojiber necrosis and selective loss of thick myofilaments. This myopathic disorder is felt to be related to the prolonged use of non-depolarizing neuromuscular blocking agents either alone or in combination with other medications or disorders. Many authors feel that the disorder is caused specifically by a combination of prolonged neuromuscular blockade and corticosteroids. Selective loss of thick myofilaments on muscle biopsy has been produced experimentally in rats by combining denervation with high doses of corticosteroids. As this disorder likely leads to additional respiratory compromise, dificulty weaning from the ventilator, and prolonged hospitalization, prevention is warranted. Methodr of prevention include minimizing the dosage of non-depolarizing neuromuscular blocking agents and of other drugs with an effect on the neuromuscular junction, twitch monitoring with a peripheral nerve stimulator and allowing patients to come to an unparalyzed state for brief periods.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.